Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-PLUS: niraparib maintenance after 3 versus 6 cycles of platinum-based chemotherapy in completely debulked advanced HRD-positive high-grade ovarian cancer
2022-502559-69-01Phase 2Authorised
- Sponsor
- NOGGO
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of niraparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by NOGGO. Primary endpoint: Recurrence-free survival. Planned start Jul 2024; status: authorised.
02
Drugs
niraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2022-502559-69-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502559-69-01.